| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;114:1432-1445.)
© 2006 American Heart Association, Inc.
AHA Scientific Statement |
| Abstract |
|---|
|
|
|---|
Methods The AHA Writing Group began with a conceptual model of disease management and its components and subsequently validated this model over a wide range of disease management programs. A systematic MEDLINE search was performed on the terms heart failure, diabetes, and depression, together with disease management, case management, and care management. The search encompassed articles published in English between 1987 and 2005. We then selected studies that incorporated (1) interventions designed to improve outcomes and/or reduce medical resource utilization in patients with heart failure, diabetes, or depression and (2) clearly defined protocols with at least 2 prespecified components traditionally associated with disease management. We analyzed the study protocols and used qualitative research methods to develop a disease management taxonomy with our conceptual model as the organizing framework.
Results The final taxonomy includes the following 8 domains: (1) Patient population is characterized by risk status, demographic profile, and level of comorbidity. (2) Intervention recipient describes the primary targets of disease management intervention and includes patients and caregivers, physicians and allied healthcare providers, and healthcare delivery systems. (3) Intervention content delineates individual components, such as patient education, medication management, peer support, or some form of postacute care, that are included in disease management. (4) Delivery personnel describes the network of healthcare providers involved in the delivery of disease management interventions, including nurses, case managers, physicians, pharmacists, case workers, dietitians, physical therapists, psychologists, and information systems specialists. (5) Method of communication identifies a broad range of disease management delivery systems that may include in-person visitation, audiovisual information packets, and some form of electronic or telecommunication technology. (6) Intensity and complexity distinguish between the frequency and duration of exposure, as well as the mix of program components, with respect to the target for disease management. (7) Environment defines the context in which disease management interventions are typically delivered and includes inpatient or hospital-affiliated outpatient programs, community or home-based programs, or some combination of these factors. (8) Clinical outcomes include traditional, frequently assessed primary and secondary outcomes, as well as patient-centered measures, such as adherence to medication, self-management, and caregiver burden.
Conclusions This statement presents a taxonomy for disease management that describes critical program attributes and allows for comparisons across interventions. Routine application of the taxonomy may facilitate better comparisons of structure, process, and outcome measures across a range of disease management programs and should promote uniformity in the design and conduct of studies that seek to validate disease management strategies.
Key Words: AHA Scientific Statements disease management chronic disease delivery of health care classificationheart failure
| Introduction |
|---|
|
|
|---|
Despite the promise offered by disease management programs, questions remain about their potential for widespread application. Randomized trials of disease management have demonstrated improved outcomes for conditions such as heart failure, diabetes mellitus, and chronic kidney disease, but these studies generally have been conducted at single sites, and it is not known how successfully their results can be generalized to larger patient populations. In addition, many disease management programs are multidimensional, and the essential program elements that are associated with efficacy have yet to be established. These challenges are further complicated by a lack of standardization: The term disease management has entered into common usage without a shared, specific understanding of its meaning. Instead, multiple definitions of disease management and a variety of related models exist. Although disease management programs generally share core elements such as risk management and coordination of care, individual program components are highly variable. This variability presents difficulties in comparing and contrasting models, programs, outcomes, and effectiveness. The heterogeneity also impedes the development of policies that will provide incentives for the provision of disease management.
In response to these challenges, the American Heart Association (AHA) formed an interdisciplinary Disease Management Taxonomy Writing Group to develop a classification system for disease management. The work of the AHA Writing Group builds on the previous efforts of the AHAs Expert Panel on Disease Management to establish core principles for the application of disease management to cardiovascular disease and stroke (Table 1).3 The taxonomy outlined in the present statement provides a conceptual framework that can be used both to compare the diverse range of disease management programs and to inform efforts to identify specific factors associated with effectiveness.
|
| Background |
|---|
|
|
|---|
Managed care organizations were among the first to adopt disease management concepts, in part because of their structure for sharing economic risk.6 Because hospital costs represent a significant portion of patients overall healthcare resource utilization, disease management strategies to reduce hospitalization rates and length of stay offered attractive financial incentives to these organizations.
Other early disease management initiatives included pharmaceutical company programs developed in response to concerns that health maintenance organizations (HMOs) might decrease payments for drugs.7 Pharmaceutical companies began identifying patients with chronic illnesses, determining their level of risk, and offering educational services to promote medication adherence and behavior change. By bundling prescription drugs with these ancillary services, companies sought to add value to their products and to increase the likelihood that they would be included on HMO formularies.8
It was not until the mid-1990s that disease management strategies were adopted by the healthcare industry on a wider scale, though still principally as a means of controlling costs. This widespread adoption coincided with a period of significant transition within the US healthcare delivery system: The promise of long-term cost savings offered by HMOs had begun to wane, and consumer dissatisfaction with managed care was high.9 At the same time, the chronic disease burden continued to drive healthcare spending and utilization rates.10 In response to these conditions, disease management emerged in the healthcare marketplace as an attractive new model for controlling costs.5
A body of medical literature evaluating disease management also began to emerge in the mid-1990s. In 1995, Rich et al11 published a landmark article that reported results of a prospective, randomized trial of a nurse-directed, multidisciplinary intervention on the rates of readmission within 90 days of hospital discharge, quality of life, and costs of care for high-risk patients
70 years of age who were hospitalized with heart failure. Readmissions for heart failure were reduced by 56%, and the program saved almost $500 for each person enrolled. The study provided strong validation for the concept of disease management and was soon followed by many other trials of disease management interventions. Phillips and colleagues,12 in a review of this literature, studied 18 trials and found that during a pooled mean observation period of 8 months, the risk of readmission was reduced by 25%.
Once the disease management trend took hold, it spread rapidly.13 Numerous healthcare companiesincluding HMOs, pharmaceutical manufacturers, pharmaceutical benefits managers, medical groups and hospitalsorganized quickly to meet the demand for comprehensive initiatives that would improve chronic disease care while reducing expenditures. By 1999, some 200 disease management programs were in place for conditions such as congestive heart failure, diabetes, and asthma.13 These disease-specific programs shared certain common features, including an integrated approach to care, patient education, and the collection of outcomes data. Ultimately, though, the proliferation of disease management programs was characterized by variety rather than uniformity. Market forces encouraged companies to develop proprietary treatment algorithms and unique component packages in an effort to gain a competitive advantage. As a result, private sector disease management developed as a diverse field exhibiting a wide range of programmatic features.
Government interest in disease management also evolved during this period. Motivated in part by private sector developments, in the late 1990s Congress authorized several demonstration projects to evaluate disease management strategies under fee-for-service Medicare (see Table 2). President Clintons 1999 Medicare Modernization proposal named disease management as an important new tool for modernizing the Medicare program.14 As part of the 2003 Medicare Modernization Act, Congress authorized Medicare Health Support, which constitutes the largest randomized evaluation of disease management to date.23 Under this pilot program, approximately 160 000 Medicare beneficiaries with congestive heart failure and complex diabetes among their chronic conditions will be randomized to either an intervention or a control group; those assigned to the intervention group will be able to accept or decline participation. Eligible beneficiaries will be identified through a population-based approach that uses Medicare claims data. Patients in the intervention group will receive guidance to promote medication adherence, self-management, and access to covered healthcare services. Disease management interventions will be delivered by private healthcare organizations, which must guarantee effective management of comorbidities, reduced healthcare costs, improved quality of care, and improved provider and patient satisfaction. After 2 years, pending successful interim results, this pilot may be expanded nationally.
|
These initiatives represent a landmark effort to determine whether disease management programs can be effective in improving health and cost outcomes for selected subgroups of chronically ill Medicare beneficiaries. Collectively, the demonstration and pilot projects comprise the largest evaluation of disease management to date, and their outcomes will undoubtedly influence future public and private sector approaches to disease management.
States also have been permitted to develop disease management programs for their primary care case management and fee-for-service Medicaid populations; to date, 28 states have done so.24 These programs may be designed and operated by health plans or state Medicaid agencies, or they may be contracted out to disease management organizations.25 Because of this flexibility, state disease management programs vary widely in their scope and impact. Many are still at an early stage of development, so effectiveness cannot be evaluated.26
| Disease Management Definitions and Related Models |
|---|
|
|
|---|
|
|
The Disease Management Association of America (DMAA), a nonprofit trade association representing stakeholders in the disease management industry, responded to this problem by publishing a comprehensive definition that has gained widespread acceptance in recent years (Table 4). However, the DMAA definition is not used universally, and many programs that fail to meet its standards are nonetheless described as disease management programs in the medical literature.28 It is also not clear that this definition can be supported empirically, as the optimal mix of ingredients for a successful disease management program is not yet known.6 For these reasons, the AHA Writing Group believes that a broad definition is necessary as research continues to define the key components associated with positive outcomes.
The development of alternative care management models, many of which are considered under the overarching heading of disease management, has further complicated the search for a standard definition. Terms such as case management, coordinated care, and multidisciplinary care have been used interchangeably with disease management, but their unique characteristics are rarely enumerated. Because disease management programs have historically provided narrowly tailored medical solutions focused on one dominant health problem, several of these alternative models have arisen in an attempt to provide a more integrated approach to care, directing attention to the wide range of patient comorbidities.29 Boundaries between models have increasingly blurred, however, as disease management programs have started to evolve to encompass both comorbid conditions and a greater constellation of outpatient services. Below is a discussion of the most commonly referenced disease managementrelated models.
| A Taxonomy for Disease Management |
|---|
|
|
|---|
The taxonomy that follows is designed to meet this need through both descriptive and prescriptive analysis. It is based on a conceptual model developed by the AHA Writing Group that was refined through a review of published reports of disease management strategies for heart failure, depression, and diabetes. A complete listing of these published reports is available as an online Data Supplement. The conditions of heart failure, depression, and diabetes were chosen because of their lengthy history as targets for disease management intervention and because of the relative abundance of published studies evaluating those interventions. Beyond this focus, however, the taxonomy is intended to be applicable to disease management programs across myriad chronic disease states and to both current and future models. The AHA Writing Group strongly encourages researchers and publishers to report the results of disease management trials according to the taxonomic framework described here. Although detailed reporting requirements may vary by study design or disease state, at a minimum, every article on disease management should include information addressing the 8 domains (and respective subdomains) of the taxonomy.
| Methods |
|---|
|
|
|---|
| Search Strategy |
|---|
|
|
|---|
Articles were selected according to the following criteria: (1) They described interventions designed to improve outcomes and/or reduce medical resource utilization in patients with heart failure, diabetes, or depression; and (2) they used clearly defined protocols incorporating at least 2 prespecified components traditionally associated with disease management (such as patient education, involvement of nonphysician personnel, or intensive follow-up). Because study outcomes were not formally evaluated or statistically compared, the review was able to accommodate a heterogeneous mix of interventions and study designs. Indeed, these broad inclusion criteria were deliberately established to encourage the assessment of a wide range of interventions to best capture the full spectrum of disease managementrelated activities.
| Taxonomy |
|---|
|
|
|---|
|
|
Because the taxonomy was refined through comparison with reports from the academic literature, its content and structure reflect the attributes of programs described in those reports. However, the taxonomy was constructed to accommodate future developments in the field. The domains and subdomains outlined below represent a framework for the content that reports of disease management should include, as well as the level of detail with which that content should be described. This framework incorporates sufficient flexibility to accommodate the evolving nature of disease management and novel approaches that may be developed in the future.
1. Patient Population
To classify disease management interventions, or to compare disease management programs, it is critical that their target patient populations be clearly defined. Although narrowly tailored selection criteria may facilitate the conduct of research, this approach fundamentally limits our ability to understand the impact of disease management in the broader population of chronically ill patients. The following subdomains should be addressed in a patient population definition.
Risk Status
The patient populations included in the review differed widely in their levels of risk. In disease management interventions for heart failure, this included variability in such important factors as age, degree of left ventricular dysfunction, and NYHA class. Among diabetes programs, patients differed in their diabetes type, degree of glycemic control, and the presence of complications. The impact of disease management can vary widely depending on the fit between the intervention and the risk status of the patient population. High-risk groupssuch as older patients, patients with a history of prior hospitalizations, and patients with significant comorbiditiesmay experience fewer hospitalizations in response to disease management. Failure to account for the risk status of the target population can therefore lead to inappropriate comparisons between interventions. For example, we could draw few meaningful conclusions about the relative efficacy of 2 programs by comparing the outcomes of the 52-year-old heart transplantation candidates studied by Fonarow et al42 with those of the 80-year-old patients with chronic heart failure examined by Ekman and colleagues.43
Medical Comorbidities
All studies included in the review identified a primary condition targeted by the disease management intervention. However, few of the reports explicitly discussed the management of comorbid conditions in addition to the primary diagnosis.4448 The remainder either excluded patients with comorbidities from participation or noted their presence without taking steps to manage those conditions. A large proportion of patients with chronic illness suffer from medical comorbidities, and some of the greatest challenges in caring for these patients involve the complex interactions of different disease states. As disease management evolves to meet the full range of medical needs experienced by chronically ill patients, programs and interventions may similarly evolve to address comorbidities more comprehensively.
Nonclinical Characteristics
In addition to defining the clinical parameters of the target population, researchers must consider other nonclinical characteristics when describing a disease management intervention. A number of studies in the review identified potentially significant patient characteristics such as education level, annual income, literacy, and marriage status. Riegel and LePetri6 have noted that the specific role played by these factors is unclear; it may vary with the nature of the disease management intervention. Patients with higher levels of education and greater self-efficacy may be more responsive to self-management strategies while exhibiting no difference in their response to medication management. A more systematic attempt to document and report nonclinical characteristics of the target population will improve the comparability of study results and may facilitate elucidation of the specific mechanisms underlying improved outcomes.
2. Intervention Recipient
The patient population that is expected to benefit from disease management (see Patient Population above) should be differentiated from the individuals who are targeted by the intervention. In most studies these 2 groups overlapped: Heart failure patients who received education about diet, exercise, and weight monitoring were also intended to receive direct benefit as a result. However, the literature also describes disease management interventions designed to benefit patients indirectly by influencing provider behavior. Under this alternative strategy, healthcare providers receive instruction (often developed from evidence-based guidelines) about optimal care for the target population, are given feedback on the results of care received by their patients, or alter the organization of care processes. In our review, the provider education approach was used less frequently in the heart failure studies reviewed4951 but was common in disease management programs for depression52 and diabetes.5358
3. Intervention Content
Intervention content is another key domain in describing any disease management program. Disease management interventions range widely from a single educational session to remote electronic monitoring to comprehensive programs involving multidisciplinary care teams. This variety reflects the perspective of those providing the intervention (eg, physician, nurse, or pharmacist), issues specific to the patient population, and the goals of the funding organization. Specifically, the content of a disease management program led by a clinical pharmacist will probably address pharmacological therapy, whereas that led by a nurse may emphasize patient education to improve self-care. A disease management program for heart failure would likely aim to reduce hospitalization costs, whereas the program for a patient with diabetes might emphasize glucose control. The content of a program funded by a hospital may address ways to shorten hospital stays, but an intervention paid for by an HMO would want to limit readmissions. These different perspectives contribute significantly to the variety found among disease management programs.
Patient education is the cornerstone of all disease management programs, and the majority of those reviewed incorporated patient education on topics such as the consequences of illness in daily life. For heart failure patients, this included recognition of warning signs of deterioration; advice on diet, fluid, and sodium management; and the importance of daily weighing. Diabetic patients received education about weight and caloric intake control, blood glucose self-monitoring, and foot measurement and care. Educational interventions also addressed behavioral strategies to improve patient compliance with prescribed diet, exercise, and medication regimens. A smaller number reinforced educational messages with ancillary materials, such as brochures or videos.
Peer support was one component that was regularly present in disease management programs for depression but has been used less frequently as part of cardiac disease management.59 In disease management for depression, peer support was provided by trained individuals, linked with study subjects of similar age and sex, who had experienced an episode of major depression. These individuals were expected to make telephone or in-person contact with the patient for at least 6 months; during these encounters, peer supporters were supposed to model and share their successful coping skills, provide emotional support, and encourage self-monitoring and continued medical treatment.
Though less structured than the peer support intervention described above, disease management programs for diabetic patients routinely educated participants in a group setting.46,48,6063 Groups ranged in size from 4 to 28 patients, and their educational content was similar to that offered in studies that used one-on-one sessions. Group education sessions were reinforced by encouraging patients to interact between sessions and by follow-up nurse contact.
4. Delivery Personnel
The type of delivery personnel is another key domain. Programs with similar patient populations and intervention content may vary substantially in the qualifications of the individuals who deliver the content, which may in turn influence program effectiveness.
The programs reviewed generally emphasized a multidisciplinary approach to care; however, the specific disciplines represented, as well as the number of personnel involved, varied significantly across programs. It has been noted elsewhere64 that the optimal mix of program delivery personnel is not yet known: Small teams may be as likely to improve outcomes as large ones, and alternative models (involving personnel such as health educators) have yet to be thoroughly explored. The following list therefore includes a range of delivery personnel commonly represented in disease management programs, but we do not claim the list to be exhaustive.
Nurses
Nursing staff were integral to nearly all of the disease management strategies included in the review. Their duties were broad in scope, consisting of patient education, inpatient and outpatient evaluations, and making treatment or patient support recommendations to physicians. Among these, the most common theme was reliance on nurse expertise to provide patient education and frequent follow-up to relay clinically relevant findings to the patients physician, thereby effecting more intensive management of the disease. In some studies, nurses also made home visits to optimize medication management, identify early signs of deterioration, and intensify medical follow-up as needed.6567
Case Managers
A subset of studies also cast nurses in the role of case manager. The precise duties associated with this title were not always clearly articulated, though it generally connoted a more supervisory role in patient care. Case managers assessed patients in person and via telephone; monitored and participated in education sessions for patients and caregivers; relayed information to patients about symptoms and medication side effects; collected information about medication use, symptoms, and vital signs; discussed patients status with treating physicians; and coordinated care with ancillary patient services, such as physical therapy or social work consultations. Some qualified case managers independently managed patients medication.
Physicians
Physician involvement tended to be greatest during the early stages of disease management intervention. Specialist physicians (cardiologists, psychiatrists, or endocrinologists) routinely conducted an initial consultation with each patient, involving a comprehensive assessment of the patients status, with follow-up review as required. This was followed by the establishment of individualized treatment plans, with particular attention to the optimization of medication. Ongoing evaluation of patients progress was performed by a combination of different personnel, including specialist physicians, nurses, and primary care physicians. Despite their inclusion in many of the interventions, however, the role of the primary care physician was variable and often ill defined. In some cases, they were encouraged to conduct regular patient monitoring and to modify the treatment plan as needed; in others, they were merely kept apprised of their patients status.
Pharmacists
A small number of studies48,66,6871 evaluated the addition of a pharmacist to the care team. In these studies, the pharmacist reviewed patient histories and medication regimens and provided recommendations to physicians to optimize drug therapy. The pharmacist also communicated directly with patients, discussing medication changes, emphasizing the importance of adherence, and conducting telephone follow-up.
Social Workers
Social workers participated in both heart failure and depression interventions to help coordinate social services. This included assessment of patients living arrangements, economic status, cognitive abilities, and existing sources of social support. Social workers also helped connect patients to legal resources, meal delivery services, therapy, and live-in caregivers.72 In one study of depression, a psychiatric social worker screened volunteers who had expressed interest in providing structured peer support for subjects.73
Dietitians
Multidisciplinary heart failure disease management programs routinely included dietitians who provided individualized dietary assessment and instruction. Dietitians were also a regular feature in diabetes disease management because of the importance of weight and blood glucose control for diabetic patients.
Physical Therapists
Patients were offered a physical therapy assessment in both heart failure and diabetes studies, and physical therapists designed personalized exercise programs to improve patients strength and endurance.
Psychologists
Although many depression disease management studies augmented physician services with nursing support, a smaller number also included psychologists among the members of the care team.74,75 Psychologists were not specifically identified in any of the heart failure or diabetes studies reviewed.
Information Systems Specialists
A subset of disease management programs used electronic devices or automated telephone messages to deliver content to patients.41,76,77,7981 In addition to monitoring clinical information such as blood pressure, weight, and blood glucose, these programs offered programmed education in areas such as medication adherence and behavior change.
5. Method of Communication
The methods used to deliver disease management interventions are increasingly important to consider, particularly as information technology has become a more prominent feature in many disease management programs. In most studies, care providers communicated directly with patients through face-to-face interaction. However, a significant number either replaced or augmented face-to-face contact with a mediated form of communication. Remote electronic monitoring systems were used in a subset of heart failure studies41,76,77,79,80 to record measurements of patients weight, blood pressure, heart rate, and oxygen saturation. These systems required the installation of electronic equipment in patients homes to transmit data to a central location via telephone or the Internet. Telephone monitoring was more common than remote electronic monitoring in heart failure, diabetes, and depression interventions. Disease management interventions that closely monitored symptoms and vital signs also tended to emphasize intensive management of patients pharmacological therapy.
Telephone contact also provided an opportunity for care providers to reinforce educational content, offer encouragement, and respond to patient questions. In one study of diabetes, an automated telephone care program was used as the primary method of patient education, with additional telephone reinforcement by a nurse educator.81
Only one study82 specified the use of the Internet as a means of transmitting educational information to patients; however, the use of advanced technology is expected to increase.
6. Intensity and Complexity
Disease management programs differ both in the intensity with which interventions are delivered and in their structural complexity. A recent systematic review of disease management interventions for depression found that patient outcomes were improved by complex strategies incorporating clinician education, nurse case management, and greater interaction between primary and secondary care. However, the same review also identified improved outcomes associated with simpler, less expensive interventions such as telephone medication counseling.83 If a basic program is able to deliver the same benefits as a more costly one, it is more likely to be implemented on a wider scale. It is therefore critical that disease management interventions are reported and analyzed not only in terms of their individual components, but also in terms of the relationship between these components and the intensity with which they are delivered.
Duration
The duration of patient participation in the disease management interventions reviewed varied significantly. Most programs typically involved structured intervention (some combination of education, medication management, and counseling) for no more than a 6-month period. A few provided less intensive telephone follow-up ranging from 3 months to 2 years.
Frequency/Periodicity
For hospital-based programs, patientprovider interaction occurred most frequently during the inpatient phase. However, outpatient interventions could also be intensive and time consuming: Ledwidge et al84 required heart failure patients to complete 3 scheduled clinic visits and 10 separate clinic-led consultations during the 3 months immediately after discharge. Home-based interventions and telephone support programs involved significantly less face-to-face contact. Stewart and Horowitz85 found evidence of reduced hospital readmissions for heart failure patients after only 1 home visit by a cardiac nurse with reinforcement by a community pharmacist, and Krumholz et al86 required only 1 in-person education session. Structured telephone contact tended to take place weekly during the immediate postdischarge period, with the frequency decreasing over time.
Complexity
The individual components of disease management contribute to overall program structure, such that disease management programs can also be characterized by their complexity. On the basis of their mix of individual components, programs were quite heterogeneous in this respect. Highly complex programs maximized the application of many different disease management components, involved a wide variety of delivery personnel, and were more likely to tailor the application to the individual needs of each patient. For example, Naylor et al87 evaluated a highly complex hospital discharge protocol administered by advanced practice nurses in conjunction with patients physicians, caregivers, and other home-based service providers. Program components included individualized discharge planning; assessment of functional, cognitive, and emotional health; extensive self-management education; and regularly scheduled home visits and telephone contact. By contrast, the least complex programs were characterized by far fewer disease management components, with fewer disciplines represented among delivery personnel and a more uniform approach to patients. A simple home-based telemonitoring intervention studied by Cordisco and colleagues41 involved only electronic transmission of patients weight and symptoms, with daily review by a nurse. Finally, programs of intermediate complexity could be recognized by the incorporation of some, but not all, of the intervention components and delivery personnel described in the preceding sections of the taxonomy. Krumholz and colleagues86 investigated a program of intermediate complexity in which heart failure patients received a nurse-led hour-long education session shortly after discharge, followed by telephone-based reinforcement for 1 year. Although the program did not provide individualized care plans, nurses could encourage physician contact during the telemonitoring phase if patients status deteriorated.
Finding a reliable coding system for complexity may be challenging, but any adequate description of a disease management program should provide a description of the operational aspects of the program. Program complexity may significantly affect clinical outcomes, intervention costs, and overall costs of care; however, few analyses have examined the association between program complexity and these factors. This is an area for further exploration, as it is important to identify the types of disease management program structure that optimize chronic care at the level of individual patients or targeted patient communities.
7. Environment
The environment in which disease management interventions are delivered also has the potential to affect both patient and financial outcomes, though it is not yet clear which environmental factors are associated with success. The majority of studies included in the review implemented disease management interventions in the outpatient setting, incorporating a mix of hospital-based clinic visits and telephone contact. In some cases (particularly those involving patients with more advanced progression of disease or limited mobility), disease management interventions were delivered in patients homes, either electronically or by program staff (see Method of Communication above). Other programs specifically targeted the hospital-to-home transition, reinforcing inpatient education and medication management with subsequent outpatient contact and monitoring.
Program environment also varied with the disease being targeted. Heart failure programs were significantly more likely to incorporate an inpatient component because of the high hospitalization rate for patients with heart failure. Alternatively, disease management interventions for depression and diabetes were more often administered from primary care clinics.
In addition to the physical location of a disease management program, organizational factors may have a significant environmental impact. Organizations responsible for funding and executing disease management programs range widely, including government agencies, health insurers, physician groups, hospitals, and private disease management companies. It is not yet known whether these different organizational environments, and the different financial motivations that accompany them, impact the cost or efficacy of disease management programs.
8. Clinical Outcomes
A description of a disease management program should also include a clear description of its goalsthat is, the outcomes it is designed to influence. Although interventions to improve patient and/or caregiver knowledge, self-care behavior, medication adherence, and overall quality of life were common components of disease management programs, outcomes specific to these interventions were not assessed or reported with consistency in the heart failure literature reviewed. Instead, patient mortality and hospital readmission rates were often the primary outcomes assessed and reported with consistency. This trend reflects a design bias in favor of programs targeting costs Reductions in readmission rates tended to reduce their costs while producing economic loss for hospitals charged with implementing disease management programs. For payers, there may be little enthusiasm for implementing disease management if it results in economic loss to the system. Few other interventions in medicine are required to be cost saving. However, a shift in the domains of program evaluation toward patient-centered outcomes such as quality of life, changes in caregiver burden, and overall societal costs may facilitate a change in perspective by hospital systems through increased demands by patients for these beneficial programs and a change in reimbursement priorities by private and public payers.
Nonhospital-based programs for depression and diabetes tended to report on a wider range of outcomes. For depression, these included medication adherence, frequency of mental health visits, satisfaction with treatment, symptoms of depression, and general mental and physical functioning. Diabetes disease management programs generally reported change in glycosylated hemoglobin value as the primary outcome measure, though secondary outcome variables, including weight, blood pressure, lipid profile, eye and foot examinations, diabetes knowledge, and health-related quality of life were also reported with regularity.
| Conclusion |
|---|
|
|
|---|
| Acknowledgments |
|---|
|
|
| Footnotes |
|---|
This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on June 16, 2006. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0371. To purchase additional reprints: Up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4121, fax 410-528-4264, or e-mail kelle.ramsay@wolterskluwer.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.
The online-only Data Supplement can be found at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.106.177322/DC1.
Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development, visit http://www.americanheart.org/presenter.jhtml?identifier=3023366.
Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.americanheart.org/presenter.jhtml?identifier=4431. A link to the "Permission Request Form" appears on the right side of the page.
| References |
|---|
|
|
|---|
2. Congressional Budget Office. An Analysis of the Literature on Disease Management Programs. October 13, 2004. Available at: http://www.cbo.gov/showdoc.cfm?index=5909&sequence=0. Accessed August 1, 2005.
3. Faxon DP, Schwamm LH, Pasternak RC, Peterson ED, McNeil BJ, Bufalino V, Yancy CW, Brass LM, Baker DW, Bonow RO, Smaha LA, Jones DW, Smith SC, Ellrodt G, Allen J, Schwartz SJ, Fonarow G, Duncan P, Horton K, Smith R, Stranne S, Shine K. Improving quality of care through disease management: principles and recommendations from the American Heart Associations Expert Panel on Disease Management. Circulation. 2004; 109: 26512654.
4. Epstein RS, Sherwood LM. From outcomes research to disease management: a guide for the perplexed. Ann Intern Med. 1996; 124: 832837.
5. Zitter M. A new paradigm in health care delivery: disease management. In: Todd WE, Nash D, eds. Disease Management: A Systems Approach to Improving Patient Outcomes. Chicago, Ill: American Hospital Publishing, Inc; 1997: 126.
6. Riegel B, LePetri B. Heart failure disease management models. In: Moser DK, Riegel B, eds. Improving Outcomes in Heart Failure: An Interdisciplinary Approach. Gaithersburg, Md: Aspen Publishers, Inc; 2001: 267281.
7. Bodenheimer T. Disease managementpromises and pitfalls. N Engl J Med. 1999; 340: 12021205.
8. Homer CJ. Asthma disease management. N Engl J Med. 1997; 337: 14611463.
9. Blendon RJ, Brodie M, Benson JM, Altman DE, Levitt L, Hoff T, Hugick L. Understanding the managed care backlash. Health Aff (Millwood). 1998; 17: 8094.[Abstract]
10. Hoffman C, Rice D, Sung HY. Persons with chronic conditions: their prevalence and costs. JAMA. 1996; 276: 14731479.
11. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995; 333: 11901195.
12. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis [published correction in JAMA. 2004;292:1022]. JAMA. 2004; 291: 13581367.
13. Bodenheimer T. Disease management in the American market. BMJ. 2000; 320: 563566.
14. Clinton Administration, National Economic Council, Domestic Policy Council. The Presidents Plan to Modernize and Strengthen Medicare for the 21st Century. July 2, 1999.
15. 65 Federal Register 46,466 (July 28, 2000).
16. 67 Federal Register 8,267 (February 22, 2002).
17. 67 Federal Register 188 (September 27, 2002).
18. 68 Federal Register 9,673 (February 28, 2003).
19. 68 Federal Register 33,495 (June 4, 2003).
20. 69 Federal Register 193 (October 6, 2004).
21. Medicare Prescription Drug, Improvement, and Modernization Act. USC
648 (2003).
22. Medicare Prescription Drug, Improvement, and Modernization Act. USC
649 (2003).
23. Medicare Prescription Drug, Improvement, and Modernization Act. USC
721 (2003).
24. Kaiser Family Foundation. Medicaid cost containment actions taken by states, FY2005. Available at: http://www.statehealthfacts.kff.org/cgi-in/healthfacts.cgi?action=compare&category=Medicaid+%26+SCHIP&subcategory=Medicaid+Cost+Containment&topic=Medicaid+Cost+Containment+Actions. Accessed May 23, 2005.
25. Wheatley B. Medicaid disease management: seeking to reduce spending by promoting health. State Coverage Initiatives Issue Brief, AcademyHealth, August 2001. Available at: http://www.statecoverage.net/pdf/issuebrief0801.pdf. Accessed May 25, 2005.
26. Gillespie JL, Rossiter LF. Medicaid disease management programs: findings from three leading US state programs. Dis Manage Health Outcomes. 2003; 11: 345361.[CrossRef]
27. Disease Management Association of America. Definition of disease management. Available at: http://www.dmaa.org/definition.html. Accessed May 25, 2005.
28. Gonseth J, Guallar-Castillón P, Banegas JR, Rodríguez-Artalejo F. The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports. Eur Heart J. 2004; 25: 15701595.
29. Brass-Mynderse NJ. Disease management for chronic congestive heart failure. J Cardiovasc Nurs. 1996; 11: 5462.[Medline] [Order article via Infotrieve]
30. Chen A, Brown R, Archibald N, Aliotta S, Fox PD. Best Practices in Coordinated Care. Centers for Medicare and Medicaid Services, US Department of Health and Human Services. March 22, 2000. MPR Reference No. 8534-004.
31. Silberman P, Poley S, Slifkin R. Innovative primary care case management programs operating in rural communities: case studies of three states. Working Paper No. 76, North Carolina Rural Health Research and Policy Analysis Program. January 3, 2003.
32. Berenson RA, Horvath J. Confronting the barriers to chronic care management in Medicare. Health Aff (Millwood). 2003; (Supp Web Exclusives): 3753.
33. Stille CJ, Jerant A, Bell D, Meltzer D, Elmore JG. Coordinating care across diseases, settings, and clinicians: a key role for the generalist in practice. Ann Intern Med. 2005; 142: 700708.
34. Schillinger D, Bibbins-Domingo K, Vranizan K, Bacchetti P, Luce JM, Bindman AB. Effects of primary care coordination on public hospital patients. J Gen Intern Med. 2000; 15: 329336.[CrossRef][Medline] [Order article via Infotrieve]
35. Vale MJ, Jelinek MV, Best JD, Dart AM, Grigg LE, Hare DL, Ho BP, Newman RW, McNeil JJ; COACH Study Group. Coaching patients On Achieving Cardiovascular Health (COACH): a multicenter randomized trial in patients with coronary disease. Arch Intern Med. 2003; 163: 27752783.
36. Lynn J, Adamson DM. Living well at the end of life: adapting health care to serious chronic illness in old age. White Paper, RAND Health WP-137 (2003). Available at: http://www.medicaring.org/whitepaper/. Accessed August 10, 2005.
37. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. Health Aff (Millwood). 2001; 20: 6478.
38. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank Q. 1996; 74: 511544.[Medline] [Order article via Infotrieve]
39. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002; 288: 17751779.
40. Siminerio L, Zgibor J, Solano FX Jr. Implementing the chronic care model for improvement in diabetes practice and outcomes in primary care: the University of Pittsburgh Medical Center experience. Clin Diabetes. 2004; 22: 5458.
41. Cordisco ME, Benjaminovitz A, Hammond K, Mancini D. Use of telemonitoring to decrease the rate of hospitalization in patients with severe congestive heart failure. Am J Cardiol. 1999; 84: 860862, A8.
42. Fonarow GC, Stevenson LW, Walden JA, Livingston NA, Steimle AE, Hamilton MA, Moriguchi J, Tillisch JH, Woo MA. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 1997; 30: 725732.[Abstract]
43. Ekman I, Andersson B, Ehnfors M, Matejka G, Persson B, Fagerberg B. Feasibility of a nurse-monitored, outpatient-care programme for elderly patients with moderate-to-severe, chronic heart failure. Eur Heart J. 1998; 19: 12541260.
44. Atienza F, Anguita M, Martinez-Alzamora N, Osca J, Ojeda S, Almenar L, Ridocci F, Vallés F, de Velasco JA. Multicenter randomized trial of a comprehensive hospital discharge and outpatient heart failure management program. Eur J Heart Fail. 2004; 6: 643652.
45. California Medi-Cal Type 2 Diabetes Study Group. Closing the gap: effect of diabetes case management on glycemic control among low-income ethnic minority populations. The California Medi-Cal Type 2 Diabetes Study. Diabetes Care. 2004; 27: 95103.
46. DEramo-Melkus GA, Wylie-Rosett J, Hagan JA. Metabolic impact of education in NIDDM. Diabetes Care. 1992; 15: 864869.[Abstract]
47. Rothman RL, DeWalt DA, Malone R, Bryant B, Shintani A, Crigler B, Weinberger M, Pignone M. Influence of patient literacy on the effectiveness of a primary care-based diabetes disease management program. JAMA. 2004; 292: 17111716.
48. Sadur CN, Moline N, Costa M, Michalik D, Mendlowitz D, Roller S, Watson R, Swain BE, Selby JJ, Javorski WC. Diabetes management in a health maintenance organization: efficacy of care management using cluster visits. Diabetes Care. 1999; 22: 20112017.
49. Costantini O, Huck K, Carlson MD, Boyd K, Buchter CM, Raiz P, Cooper GS. Impact of a guideline-based disease management team on outcomes of hospitalized patients with congestive heart failure. Arch Intern Med. 2001; 161: 177182.
50. Mueller TM, Vuckovic KM, Knox DA, Williams RE. Telemanagement of heart failure: a diuretic treatment algorithm for advanced practice nurses. Heart Lung. 2002; 31: 340347.[CrossRef][Medline] [Order article via Infotrieve]
51. Philbin EF, Rocco TA, Lindenmuth NW, Ulrich K, McCall M, Jenkins PL. The results of a randomized trial of a quality improvement intervention in the care of patients with heart failure. The MISCHF Study Investigators. Am J Med. 2000; 109: 443449.[CrossRef][Medline] [Order article via Infotrieve]
52. Weingarten S, Henning JM, Badamgarav E, Knight K, Hasselblad V, Gano A Jr, Ofman JJ. Interventions used in disease management programmes for patients with chronic illnesswhich ones work? Meta-analysis of published reports. BMJ. 2002; 325: 925932.
53. Integrated care for diabetes: clinical, psychosocial, and economic evaluation. Diabetes Integrated Care Evaluation Team. BMJ. 1994; 308: 12081212.
54. Domenech MI, Assad D, Mazzei ME, Kronsbein P, Gagliardino JJ. Evaluation of the effectiveness of an ambulatory teaching/treatment programme for non-insulin dependent (type 2) diabetic patients. Acta Diabetol. 1995; 32: 143147.[CrossRef][Medline] [Order article via Infotrieve]
55. Kinmonth AL, Woodcock A, Griffin S, Spiegal N, Campbell MJ. Randomised controlled trial of patient centred care of diabetes in general practice: impact on current wellbeing and future disease risk. The Diabetes Care From Diagnosis Research Team. BMJ. 1998; 317: 12011208.
56. Kulkarni K, Castle G, Gregory R, Holmes A, Leontos C, Powers M, Snetselaar L, Splett P, Wylie-Rosett J, for the Diabetes Care and Education Dietetic Practice Group. Nutrition Practice Guidelines for Type 1 Diabetes Mellitus positively affect dietitian practices and patient outcomes. The Diabetes Care and Education Dietetic Practice Group. J Am Diet Assoc. 1998; 98: 6270.[CrossRef][Medline] [Order article via Infotrieve]
57. OConnor PJ, Rush WA, Peterson J, Morben P, Cherney L, Keogh C, Lasch S. Continuous quality improvement can improve glycemic control for HMO patients with diabetes. Arch Fam Med. 1996; 5: 502506.
58. Vinicor F, Cohen SJ, Mazzuca SA, Moorman N, Wheeler M, Kuebler T, Swanson S, Ours P, Fineberg SE, Gordon EE, Duckworth W, Norton JA, Fineberg NS, Clark CM Jr. DIABEDS: a randomized trial of the effects of physician and/or patient education on diabetes patient outcomes. J Chron Dis. 1987; 40: 345356.[CrossRef][Medline] [Order article via Infotrieve]
59. Riegel B, Carlson B. Is individual peer support a promising intervention for persons with heart failure? J Cardiovasc Nurs. 2004; 19: 174183.[Medline] [Order article via Infotrieve]
60. Aubert RE, Herman WH, Waters J, Moore W, Sutton D, Peterson BL, Bailey CM, Koplan JP. Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization. Ann Intern Med. 1998; 129: 605612.
61. De Weerdt I, Visser AP, Kok GJ, de Weerdt O, van der Veen EA. Randomized controlled multicentre evaluation of an education programme for insulin-treated diabetic patients: effects on metabolic control, quality of life, and costs of therapy. Diabet Med. 1991; 8: 338345.[Medline] [Order article via Infotrieve]
62. Raz I, Soskolne V, Stein P. Influence of small-group education sessions on glucose homeostasis in NIDDM. Diabetes Care. 1988; 11: 6771.[Abstract]
63. Taylor CB, Miller NH, Reilly KR, Greenwald G, Cunning D, Deeter A, Abascal L. Evaluation of a nurse-care management system to improve outcomes in patients with complicated diabetes. Diabetes Care. 2003; 26: 10581063.
64. Windham BG, Bennett RG, Gottlieb S. Care management interventions for older patients with congestive heart failure. Am J Manag Care. 2003; 9: 447459.[Medline] [Order article via Infotrieve]
65. Blue L, Lang E, McMurray JJ, Davie AP, McDonagh TA, Murdoch DR, Petrie MC, Connolly E, Norrie J, Round CE, Ford I, Morrison CE. Randomised controlled trial of specialist nurse intervention in heart failure. BMJ. 2001; 323: 715718.
66. Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med. 1998; 158: 10671072.
67. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet. 1999; 354: 10771083.[CrossRef][Medline] [Order article via Infotrieve]
68. Bouvy ML, Heerdink ER, Urquhart J, Grobbee DE, Hoes AW, Leufkens HG. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study [published correction in J Card Fail. 2003;9:481]. J Card Fail. 2003; 9: 404411.[CrossRef][Medline] [Order article via Infotrieve]
69. Gattis WA, Hasselblad V, Whellan DJ, OConnor C. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study. Arch Intern Med. 1999; 159: 19391945.
70. Davidson MB. Effect of nurse-directed diabetes care in a minority population. Diabetes Care. 2003; 26: 22812287.
71. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother. 1996; 30: 238243.[Abstract]
72. Riegel B, Thomason T, Carlson B, Bernasconi B, Hoagland P, Maringer D, Watkins J. Implementation of a multidisciplinary disease management program for heart failure patients. Congest Heart Fail. 1999; 5: 164170.[Medline] [Order article via Infotrieve]
73. Hunkeler E, Meresman JF, Hargreaves WA, Fireman B, Berman WH, Kirsch AJ, Groebe J, Hurt SW, Braden P, Getzell M, Feigenbaum PA, Peng T, Salzer M. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. Arch Fam Med. 2000; 9: 700708.
74. Katon W, Von Korff M, Lin E, Walker E, Simon GE, Bush T, Robinson P, Russo J. Collaborative management to achieve treatment guidelines: impact on depression in primary care. JAMA. 1995; 273: 10261031.
75. Katon W, Robinson P, Von Korff M, Lin E, Bush T. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry. 1996; 53: 924932.
76. Benatar D, Bondmass M, Ghitelman J, Avitall B. Outcomes of chronic heart failure. Arch Intern Med. 2003; 163: 347352.
77. De Lusignan S, Wells S, Johnson P, Meredith K, Leatham E. Compliance and effectiveness of 1 years home telemonitoring: the report of a pilot study of patients with chronic heart failure. Eur J Heart Fail. 2001; 3: 723730.
78. DeBusk RF, Miller NH, Parker KM, Bandura A, Kraemer HC, Cher DJ, West JA, Fowler MB, Greenwald G. Care management for low-risk patients with heart failure: a randomized controlled trial. Ann Intern Med. 2004; 141: 606613.
79. Goldberg LR, Piette JD, Walsh MN, Frank TA, Jaski BE, Smith AL, Rodriguez R, Mancini DM, Hopton LA, Orav EJ, Loh E; WHARF Investigators. Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring in Heart Failure (WHARF) trial. Am Heart J. 2003; 146: 705712.[CrossRef][Medline] [Order article via Infotrieve]
80. Heidenreich P, Ruggerio CM, Massie BM. Effect of a home monitoring system on hospitalization and resource use for patients with heart failure. Am Heart J. 1999; 138 (4 part 1): 663640.[CrossRef][Medline] [Order article via Infotrieve]
81. Piette JD, Weinberger M, Kraemer FB, McPhee SJ. Impact of automated calls with nurse follow-up on diabetes treatment outcomes in a Department of Veterans Affairs health care system. Diabetes Care. 2001; 24: 202208.
82. Villagra VG, Ahmed T. Effectiveness of a disease management program for patients with diabetes. Health Aff (Millwood). 2004; 23: 255266.
83. Gilbody S, Whitty P, Grimshaw J, Thomas R. Education and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA. 2003; 289: 31453151.
84. Ledwidge M, Ryan E, OLoughlin C, Ryder M, Travers B, Kieran E, Walsh A, McDonald K. Heart failure care in a hospital unit: a comparison of standard 3-month and extended 6-month programs. Eur J Heart Fail. 2005; 7: 385391.
85. Stewart S, Horowitz JD. Home-based intervention in congestive heart failure: long-term implications on readmission and survival. Circulation. 2002; 105: 28612866.
86. Krumholz HM, Amatruda J, Smith GL, Mattera JA, Roumanis SA, Radford MJ, Crombie P, Vaccarino V. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol. 2002; 39: 8389.
87. Naylor MD, Brooten D, Campbell R, Jacobsen BS, Mezey MD, Pauly MV, Schwartz JS. Comprehensive discharge planning and home follow-up of hospitalized elders: a randomized clinical trial. JAMA. 1999; 281: 613620.
This article has been cited by other articles:
![]() |
American College of Cardiology Foundation, American Heart Association, American College of Physicians Task Force on Compe, American Academy of Neurology, American Association of Cardiovascular and Pulmona, American College of Preventive Medicine, American Diabetes Association, American Society of Hypertension, Association of Black Cardiologists, National Lipid Association, et al. ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease. J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1336 - 1363. [Full Text] [PDF] |
||||
![]() |
WRITING COMMITTEE MEMBERS, C. N. Bairey Merz, M. J. Alberts, G. J. Balady, C. M. Ballantyne, K. Berra, H. R. Black, R. S. Blumenthal, M. H. Davidson, S. B. Fazio, et al. ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease: A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): Developed in Collaboration With the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association Circulation, September 29, 2009; 120(13): e100 - e126. [Full Text] [PDF] |
||||
![]() |
A. M. Clark, L. A. Savard, and D. R. Thompson What is the strength of evidence for heart failure disease-management programs? J. Am. Coll. Cardiol., July 28, 2009; 54(5): 397 - 401. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sochalski, T. Jaarsma, H. M. Krumholz, A. Laramee, J. J.V. McMurray, M. D. Naylor, M. W. Rich, B. Riegel, and S. Stewart What Works In Chronic Care Management: The Case Of Heart Failure Health Aff., January 1, 2009; 28(1): 179 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Spertus Evolving Applications for Patient-Centered Health Status Measures Circulation, November 11, 2008; 118(20): 2103 - 2110. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Bocchi, F. Cruz, G. Guimaraes, L. F. Pinho Moreira, V. S. Issa, S. M. Ayub Ferreira, P. R. Chizzola, G. E. C. Souza, S. Brandao, and F. Bacal Long-Term Prospective, Randomized, Controlled Study Using Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure Outpatients: The REMADHE Trial Circ Heart Fail, July 1, 2008; 1(2): 115 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Szecsenyi, T. Rosemann, S. Joos, F. Peters-Klimm, and A. Miksch German Diabetes Disease Management Programs Are Appropriate for Restructuring Care According to the Chronic Care Model: An evaluation with the Patient Assessment of Chronic Illness Care instrument Diabetes Care, June 1, 2008; 31(6): 1150 - 1154. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Alter MD PhD Therapeutic lifestyle and disease-management interventions: pushing the scientific envelope Can. Med. Assoc. J., October 9, 2007; 177(8): 887 - 889. [Full Text] [PDF] |
||||
![]() |
A. M. Davis, L. M. Vinci, T. M. Okwuosa, A. R. Chase, and E. S. Huang Cardiovascular Health Disparities: A Systematic Review of Health Care Interventions Med Care Res Rev, October 1, 2007; 64(5_suppl): 29S - 100S. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |